Big changes are happening at Axovant Gene Therapies Ltd. (NASDAQ:AXGT), which makes the stock worth watching today. The company is among the top losers of the stock market today, sinking -3.67% or (-0.18 points) to $4.73 from its previous close of $4.91. Does this decline mean it the best stock to buy right now? The shares seem to have an active trading volume day with a reported 112851 contracts so far this session. AXGT shares had a relatively better volume day versus average trading capacity of 167.51 thousand shares, but with a 9.44 million float and a -5.94% run over a week, it’s definitely worth keeping an eye on. The one year price forecast for AXGT stock indicates that the average analyst price target is $22.67 per share. This means the stock has a potential increase of 379.28% from where the AXGT share price has been trading recently.
During the recent trading session for Axovant Gene Therapies Ltd. (NASDAQ:AXGT), the company witnessed their stock drop by $-0.37 over a week and tumble down $-1.18 from the price 20 days ago. When compared to their established 52-week high of $19.6, the high they recorded in their recent session happens to be higher. Their established 52-week high was attained by the company on 11/03/19. The recent low of $3.81 stood for a -75.87% since 11/06/19, a data which is good for most investors who are looking to take advantage of the stock’s recent rise. A beta of 1.15 is also allocated to the stock. Since the beta is greater than one, it implies that the stock is more volatile than the market, a data that traders are keeping close attention to.
Looking at the current readings for Axovant Gene Therapies Ltd., the two-week RSI stands at 41.23. This figure suggests that AXGT stock, for now, is neutral, meaning that the shares are stable in terms of price movement. The stochastic readings, on the other hand, based on the current AXGT readings is similarly very revealing as it has a stochastic reading of 23.87% at this stage. This figure means that AXGT share price today is being overbought.
Technical chart claims that Axovant Gene Therapies Ltd. (AXGT) would settle between $5.16/share to $5.4/share level. However, if the stock price goes below the $4.76 mark, then the market for Axovant Gene Therapies Ltd. becomes much weaker. If that happens, the stock price might even plunge as low as $4.6 for its downside target. The stock is currently in the red zone of MACD, with the indicator reading -0.13. Traders are always alerted for the move of a stock above or below the zero line due to the fact that the reading is an indicator of the position of the short-term average relative to the long-term average. If the MACD is above the zero line, then the short-term average relative is above that of the long-term average, thus implying an upward momentum. Vice versa is the case if the MACD is below the zero line.
Analysts at Chardan Capital Markets lifted target price for shares of AXGT but were stick to Buy recommendation for the stock in their opinion released on October 28. The price target has been raised from $10 to $15. Robert W. Baird analysts bumped their rating on Axovant Gene Therapies Ltd. (NASDAQ:AXGT) stock from Neutral to Outperform in a separate flash note issued to investors on August 12. Analysts at SVB Leerink, made their first call for the equity with a Outperform recommendation, according to a research note that dated back to June 21.
AXGT equity has an average rating of 2.33, with the figure leaning towards a bullish end. 7 analysts who tracked the company were contacted by Reuters. Amongst them, 1 rated the stock as a hold while the remaining 6 were split even though not equally. Some analysts rate the stock as a buy or a strong buy while no rated it as a sell. 6 analysts rated Axovant Gene Therapies Ltd. (NASDAQ:AXGT) as a buy or a strong buy while not a single analyst advised that investors should desist from purchasing the stock or sell them if they already own the company’s stock.